CERSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
CERUS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$2.22+0.04 (+1.83%)
Close on Oct 19, 2026
- Market cap
- $445.25M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
-3.7%+47.3 pts over 5 years
Net margin
-6.7%+45.7 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +16.1% | +7.5% | +15.4% | +21.2% | |
| Free cash flow | -87.0% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -82.5% | -74.4% | -26.0% | |
| Return on assets | -51.8% | -30.9% | -7.4% | |
| Current ratio | 3.50 | 3.06 | 1.73 | |
| Interest coverage | -25.1× | -15.6× | -1.0× | |
| Inventory turnover | 1.9× | 1.9× | – | |
| Capex to revenue | 1.4% | 1.4% | 1.6% | |
| Diluted shares | 102M | 164M | 191M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cerus generated $118.90M from operations and spent $14.07M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$118.90M
Used
$14.07M
Capital expenditure$14.07M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-6.7%
×Asset turnover1.11×
×Equity multiplier3.51×
=Return on equity, FY2025-26.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -6.7% | 1.11× | 3.51× | -26.0% |
| FY2024 | -10.4% | 1.01× | 3.66× | -38.5% |
| FY2023 | -20.1% | 0.90× | 3.46× | -62.3% |
| FY2022 | -22.7% | 0.83× | 2.99× | -56.2% |
| FY2021 | -34.1% | 0.70× | 2.44× | -57.7% |
| FY2020 | -52.4% | 0.59× | 2.41× | -74.4% |
| FY2019 | -76.0% | 0.57× | 2.32× | -100.6% |
| FY2018 | -75.7% | 0.58× | 2.12× | -93.3% |
| FY2017 | -118.0% | 0.51× | 2.09× | -125.3% |
| FY2016 | -160.2% | 0.32× | 1.59× | -82.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$15.63M
- Cash generatingOperating cash flow above zero$4.84M
- Return on assets improvedROA up on the prior year-10.6% → -7.8%
- Earnings backed by cashOperating cash flow above net income$4.84M vs -$15.63M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.39 → 1.73
- No dilutionShare count did not rise185M → 191M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose1.02 → 1.16